Unknown Manufacturer
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
RDEA806 binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
